Filing Flows › Comparisons › LGND vs PGEN
Ligand Pharmaceuticals vs Precigen: LGND and PGEN compared
Ligand Pharmaceuticals is the larger company: $78.7M of revenue in its latest quarter (Q3 2026) against $74.1M for Precigen (Q3 2026). Precigen is growing faster (25× against -32% a year earlier). Precigen is more profitable, with an operating margin of 52.1% against -20.0%.
Where the money goes: LGND and PGEN
Ligand Pharmaceuticals (LGND) · Q3 2026
Ligand Pharmaceuticals, Q3 2026: revenue $78.7M (-32% year over year), operating margin -20.0%, net loss $28.5M, operating cash flow −$27.6M. The chart follows the revenue to costs, profit and cash.
Precigen (PGEN) · Q3 2026
Precigen, Q3 2026: revenue $74.1M (25× year over year), operating margin 52.1%, net earnings $35.8M, operating cash flow $11.9M. The chart follows the revenue to costs, profit and cash.
| Ligand Pharmaceuticals (LGND) | Precigen (PGEN) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $78.7M | $74.1M |
| Revenue growth, Y/Y | -32% | 25× |
| Operating margin | -20.0% | 52.1% |
| Net earnings | −$28.5M | $35.8M |
| Net margin | -36.2% | 48.2% |
| Operating cash flow | −$27.6M | $11.9M |
| Free cash flow | — | $11.4M |
Where the revenue comes from
Ligand Pharmaceuticals
- Revenue from intangible royalty assets: $47.2M (60%)
- Ojemda: $7.0M (9%)
- Other: $6.7M (8%)
- Capvaxive: $3.8M (5%)
Precigen
- Product revenues, net: $73.0M (98%)
- Service revenues: $1.2M (2%)
Questions
Which is bigger, Ligand Pharmaceuticals or Precigen?
Ligand Pharmaceuticals is the larger company: $78.7M of revenue in its latest quarter (Q3 2026) against $74.1M for Precigen (Q3 2026).
Is Ligand Pharmaceuticals or Precigen growing faster?
Precigen is growing faster (25× against -32% a year earlier).
Which is more profitable, Ligand Pharmaceuticals or Precigen?
Precigen is more profitable, with an operating margin of 52.1% against -20.0%.
More: Ligand Pharmaceuticals earnings · how Ligand Pharmaceuticals makes money · Precigen earnings · how Precigen makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 30, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.